Yabao Pharmaceutical Group Co. Ltd.
- Country
- Ownership
- -
- Established
- 1999-01-26
- Employees
- 2.2K
- Market Cap
- -
- Website
- www.yabao.com.cn
- Introduction
The company takes “join hands with health to create an oasis of life” as its corporate mission, integrating R&D, production, sales, logistics, and cultivation of Chinese herbal medicines and medicinal products. Mainly engaged in R&D, production and sales of pharmaceutical products. The company's main products include Chinese and Western medicine preparations, adhesives, APIs and pharmaceutical packaging materials. Corporate honors: National Certified Enterprise Technology Center; Advanced Collective; China's Outstanding Quality and Credit Construction Enterprise; “2022 China Innovative Pharmaceutical Enterprise”; “2022 Top 100 Chinese Medicine Enterprises”, 39th place. It received honors such as “China's Top 100 Pharmaceutical Industry Enterprises of the Year” and “2022 Best Industrial Enterprise in China Pharmaceutical R&D Product Line” from the China Pharmaceutical Industry Information Center, and won honors such as the “Shipkin Award”, the highest honor in the industry.
Clinical Trials
0
Trial Phases
0 Phases
Drug Approvals
251
Drug Approvals
Phloroglucinol Injection
- Product Name
- 间苯三酚注射液
- Approval Number
- 国药准字H20253636
- Approval Date
- Mar 18, 2025
Nifedipine Controlled-release Tablets
- Product Name
- 硝苯地平控释片
- Approval Number
- 国药准字H20244594
- Approval Date
- Jul 30, 2024
Mosapride Citrate Tablets
- Product Name
- 枸橼酸莫沙必利片
- Approval Number
- 国药准字H20090158
- Approval Date
- Feb 29, 2024
- Prev
- 1
- 2
- 3
- 4
- 5
- 26
- Next